Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Will Spare Irish Facility
by Michael McCoy
October 22, 2012
| A version of this story appeared in
Volume 90, Issue 43
GlaxoSmithKline has decided to keep operating a pharmaceutical manufacturing plant in Sligo, Ireland, that had been slated for closure. GSK got the plant in 2009 as part of its acquisition of the skin disease treatment firm Stiefel. With support from IDA Ireland, the country’s business development agency, GSK will invest about $13 million to convert the plant into a personal care products facility. Employment will decrease from 180 today to 120 during a two-year transition period, but GSK says 50 jobs will be added at that point.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter